Market Capitalization (Millions $) |
1,322 |
Shares
Outstanding (Millions) |
106 |
Employees |
50 |
Revenues (TTM) (Millions $) |
244 |
Net Income (TTM) (Millions $) |
97 |
Cash Flow (TTM) (Millions $) |
-104 |
Capital Exp. (TTM) (Millions $) |
19 |
Point Biopharma Global Inc
Point Biopharma Global Inc is a rapidly growing company in the biopharmaceutical industry. The company is focused on the development, manufacturing, and commercialization of radiopharmaceuticals for the treatment of cancer. They are driven by a mission to discover, develop and deliver innovative therapies for the benefit of cancer patients around the world.
Point Biopharma Global Inc has a strong leadership team with extensive experience in the pharmaceutical industry. In addition, the company has a strategic collaboration with Endo International plc to develop and commercialize injectable radiopharmaceutical products. This collaboration enables Point Biopharma to leverage Endo's established infrastructure, scale, and expertise in the pharmaceutical industry.
The company has a portfolio of radiopharmaceuticals in various stages of development, including its lead candidate, PNT2002, for the treatment of neuroendocrine tumors. PNT2002 is a targeted therapy that selectively delivers radiation to cancer cells while sparing normal tissue. The company is also developing PNT2006 for the treatment of follicular lymphoma and other hematologic malignancies.
To ensure that their radiopharmaceutical products meet the highest quality standards, Point Biopharma has established a state-of-the-art manufacturing facility in Indianapolis, Indiana. The facility is equipped with advanced technology and equipment to manufacture radiopharmaceutical products in compliance with FDA regulations.
Point Biopharma Global Inc is committed to bringing innovative cancer treatments to patients in need. Their dedication to improving the lives of cancer patients has earned them recognition in the industry and among the medical community as a company that is poised to make a significant impact in the fight against cancer.
Company Address: 4850 West 78th Street Indianapolis, 46268 IN
Company Phone Number: 543-9957 Stock Exchange / Ticker: NASDAQ PNT
PNT is expected to report next financial results on March 26, 2024. |
|
|